Press Releases

Media Inquiries - media@caredxinc.com

Date	Title and Summary	Additional Formats
Toggle Summary Jan 13, 2020	CareDx Reports Preliminary Fourth Quarter and Full Year 2019 Results SOUTH SAN FRANCISCO, Calif. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today	View HTML
Toggle Summary Jan 10, 2020	CareDx’s AlloSeq cfDNA Awarded CE Mark Approval CE mark approval enables global availability of dd-cfDNA measurement for monitoring transplant health SOUTH SAN FRANCISCO, Calif. , Jan. 10, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of	View HTML
Toggle Summary Jan 09, 2020	CareDx Leadership at ASTS Meeting CareDx’s Presence at the American Society of Transplant Surgeons Winter Symposium SOUTH SAN FRANCISCO, Calif. , Jan. 09, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically	View HTML
Toggle Summary Jan 08, 2020	CareDx's False Advertising Complaint Upheld By Court SOUTH SAN FRANCISCO, Calif. , Jan. 08, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today	View HTML
Toggle Summary Dec 24, 2019	CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif. , Dec. 24, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced	View HTML
Toggle Summary Dec 23, 2019	CareDx Supports Bipartisan Legislation to Protect Kidney Transplant Patients Congress introduces a bill to extend Medicare coverage of immunosuppressive medications for kidney transplant recipients BRISBANE, Calif. , Dec. 23, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization	View HTML
Toggle Summary Nov 19, 2019	CareDx to Participate in Upcoming Investor Conferences BRISBANE, Calif. , Nov. 19, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced	View HTML
Toggle Summary Nov 06, 2019	CareDx at ASN Kidney Week AlloSure highlighted at the American Society of Nephrology Conference BRISBANE, Calif. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value	View HTML
Toggle Summary Nov 04, 2019	CareDx Advances Patient Care with AlloSure 3.0 CareDx drives continued transplant focused improvements to AlloSure BRISBANE, Calif. , Nov. 04, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare	View HTML
Toggle Summary Oct 31, 2019	CareDx Reports Third Quarter 2019 Results AlloSure momentum drives 60% third quarter revenue growth BRISBANE, Calif. , Oct. 31, 2019 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare	View HTML